Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies (Review)

International Journal of Oncology

Volumn 12, Issue 4, 1998, Pages 911-920

  Rabbani, Shafaat Ahmed ^a   Xing, Rosie Hongmei ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Hormone dependent malignancies; Urokinase; Urokinase receptor

Indexed keywords

4 IODOBENZO[B]THIOPHENE 2 CARBON AMIDINE; ANTINEOPLASTIC AGENT; B 428; TAMOXIFEN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HORMONAL REGULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; REVIEW; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031892133     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Russo J and Russo IH: The etiopathogenesis of breast cancer prevention. Cancer Lett 90: 81-89, 1995.
2. Franks LM: Etiology, epidemiology, and pathology of prostate cancer. Cancer 32: 1092-1095, 1973.
3. Vessey MP: The involvement of oestrogen in the development and progression of breast disease: epidemiological evidence. In: Estrogen and the Human Breast. Beck JS (ed). Vol. 95. The Royal Society of Edinburgh, pp35-48, 1989.
4. Osborne CK, Yochmowitz MG, Knight WA III and McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 12: 2884-2888, 1980.
5. McGuire WL, Chamness GC and Fuqua SAW: Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5: 1571-1577, 1991.
6. McGuire WL: Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428-433, 1978.
7. Kitzenellenbogen BS: Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83: 1434-1435, 1991.
8. Clarke R, Thompson EW, Leonessa F, Lippman J, McGarvey M, Frandsen TL and Brünner N: Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treatment 24: 227-239, 1993.
9. Hortobagyi G: Bone metastases in breast cancer patients. Semin Oncol 18: 11-15, 1991.
10. Andersen TI: Genetic heterogeneity in breast cancer susceptibility. Acta Oncol 35: 407-410, 1996.
11. Berns EM, Foekens JA, van Staveren IL, van Putten WL, De Koning HY, Portengen H and Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18, 1995.
12. Holmquist GP and Gao S: Somatic mutation theory, DNA repair rates, and the molecular epidemiology of P53 mutations. Mutat Res 386: 69-101, 1997.
13. Engels K, Fox SB and Harris AL: Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. EXS 79: 113-156, 1997.
14. Dickson RB, Johnson MD, Bano M, Shi E, Kurebayashi J, Ziff B, Martinez-Lacaci I, Amundadottir LT and Lippman ME: Growth factors in breast cancer. Mitogenesis to transformation. J Steroid Biochem Mol Biol 43: 69-78, 1992.
15. Andreasen PA, Kjøller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
16. Montcourrier P, Mangeat PH, Salazzar G, Morisset M, Sahuquet A and Rochefort H: Cathepsin D in breast cancer cells can digest extracellular matrix in large acid vesicles. Cancer Res 50: 6045-6054, 1990.
17. Harris AL: Antiangiogenesis for cancer therapy. Lancet 349: 13-15, 1997.
18. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
19. Beherens J: The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat 24: 175-184, 1993.
20. Boyd D: Invasion and metastasis. Cancer Metastasis Rev 15: 77-89, 1996.
21. Saksela O and Rifkin DB: Cell-associated plasminogen activation. Regulation and physiological functions. Am Rev Cell Biol 4: 93-126, 1988.
22. Bernhard EJ, Gruber SB and Muschel KJ: Direct evidence linking matrix metalloproteases 9 (92 kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91: 4293-4297, 1994.
23. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M and Pyke C: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8: 189-203, 1994.
24. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F and Danø K: Cellular receptor for urokinase plasminogen activator. Carboxyl terminal processing and membrane anchoring by glycosylphosphatidyl inositol. J Biol Chem 266: 1926-1933, 1991.
25. Collen D: On the regulation of fibrinolysis. Thromb Haemost 43: 77-89, 1980.
26. Danø K, Andreasen PA, Grondahl-Hansen K, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
27. Belin D, Vassalli JD, Combepine C, Godeau F, Nagamine Y, Reich E, Kocher HP and Duboisin RM: Cloning nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur J Biochem 148: 225-232, 1985.
28. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL and Goeddel DV: Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301: 214-221, 1983.
29. Chucholowski N, Schmitt M, Gorctzki I, Schüren E, Moniwa N, Weidle U, Kramer M, Wagner D, Jänicke F and Graeff IL: Flow cytofluorometry in tumor cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA). Biochem Soc Trans 20: 208-216, 1991.
30. Vassalli JD, Baccino D and Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen-activator, urokinase. J Cell Biol 100: 86-92, 1985.
31. Mignatti P, Robbins E and Rifkin DB: Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47: 487-498, 1986.
32. Fibbi G, Ziehe M, Morbidelli L, Magnelli L and Del Rosso M: Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 179: 385-395, 1988.
33. Sprengers ED and Kluft C: Plasminogen activator inhibitors. Blood 69: 381-387, 1987.
34. Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195, 1993.
35. Steffens GJ, Günzler WA, Otting F, Frankus E and Flohé L: The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe-Seyler Z. Physiol Chem 363: 1043-1058, 1982.
36. Appella E, Robinson EA, Ullrich SJ, Stupelli MP, Corti A, Cassani G and Blasi F: The receptor-binding sequence of urokinase: a biological function for the growth factor module of proteases. J Biol Chem 262: 4437-4440, 1987.
37. Rabbani SA: Structure function requirements of urinary plasminogen activator (uPA) and its receptor. In: Cell Adhesion and Invasion in Cancer Metastasis. Brodt P (ed). RG Landes Co., pp99-111, 1995.
38. Kariko K, Juo A, Boyd D, Okada SS, Clines DB and Barnathan ES: Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 53: 3109-3117, 1993.
39. Rabbani SA, Dcsjardins J, Bell AW, Banville D, Mazar A, Henkin J and Goltzman D: An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 173: 1058-1064, 1990.
40. 2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol 172: 137-145, 1997.
41. Ruther U, Garber C, Komitowski D, Muller R and Wagner EF: Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 325: 412-416, 1987.
42. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appela E and Blasi F: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467-474, 1990.
43. Kristensen P, Eriksen J, Blasi F and Danø K: Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 115: 1763-1771, 1991.
44. Rabbani SA, Rajwans N, Achbarou A, Murthy KK and Goltzman D: Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. FEBS Lett 338: 69-74, 1994.
45. Vassalli JD: The urokinase receptor. Fibrinolysis 8: 172-181, 1994.
46. Danø K, Behrendt M, Brünner N, Ellis V, Plough M and Pyke C: The urokinase receptor protein structure and role of plasminogen activator and cancer invasion. Fibrinolysis 8: 189-202, 1994.
47. Blasi F: The urokinase receptor and cell migration. Semin Thromb Hemostasis 22: 513-516, 1996.
48. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S and Chapman HA: Identification of the urokinase receptor as an adhesion receptor for vibronectin. J Biol Chem 269: 32380-32388, 1994.
49. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman UA: Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555, 1996.
50. Gyetko MR, Todd RF III, Wilkinson CC and Sitrin RG: The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93: 1380-1387, 1994.
51. Carmeliet P, Schoojans L, Kieckens L, Ream B, Degen JL, Bronson R, Devos R, van den Ord JOJ, Colleen D and Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424, 1994.
52. Bugge TH, Suh TT, Flick MJ, Daugherty CC, Rømer J, Solberg H, Ellis Danø K and Degen JL: The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 270: 16886-16894, 1995.
53. Bugge TH, Flick MJ, Daugherty CC and Degen JL: Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9: 794-807, 1995.
54. Chiarodo A: National Cancer Institute roundtable on prostate cancer: future research directions. Cancer Res 51: 2498-2505, 1991.
55. Shi XB, Gumerlock PH and De Vere White RW: Molecular biology of prostate cancer. World J Urol 14: 318-328, 1996.
56. Hollas W, Blasi F and Boyd D: Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 51: 3690-3695, 1991.
57. Peterson H, Brunner H, Francis D, Osterland K, Rønne E, Hansen HH, Danø K and Grøndahl-Hansen J: Prognostic impact of urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675, 1994.
58. Kirchheimer J, Koller A and Binder BR: Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. Biochim Biophys Acta 797: 256-265, 1984.
59. Van Veldhuizen PJ, Sadasivan R, Cherian R and Wyatt A: Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci 312: 8-11, 1996.
60. Goltzman D, Bolivar I, Moroz LA and Rabbani SA: Urokinase and the mechanism of osteoblastic metastases by prostate cancer. Fibrinolysis 6: 63-69, 1992.
61. Connolly JM, Sun XG and Rose DP: A comparison of the expression of the malignant phenotype in two androgen-independent human prostate cancer cell lines after orthotopic implantation in nude mice. Int J Oncol 11: 771-776, 1997.
62. Achbarou A, Kaiser S, Tremblay G, Sainte-Marie LG, Brodt P, Goltzman D and Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377, 1994.
63. Crowley CW, Cohen RL, Lucas BK, Liu BK, Shuman MA and Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90: 5021-5025, 1993.
64. Jänicke F, Schmitt M and Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostasis 17: 303-312, 1991.
65. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Linen HJ: Urokinase-plasminogen activator, a marker for aggressive breast cancer. Cancer 62: 531-533, 1988.
66. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ and Andreasen PA: Urokinase plasminogen activator as a prognostic marker in. different subgroups of patients with breast cancer. Cancer 74: 2276-2280, 1994.
67. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G and Esposito G: Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198-3206, 1993.
68. Pyke C, Graem N, Ralfkiaer E, Rønne E, Høyer-Hansen G, Brünner N and Danø K: The receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911-1915, 1993.
69. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993.
70. Ramshaw IA and Badenoch-Jones P: Studies on rat mammary adenocarcinomas: a model for metastasis. Cancer Metastasis Rev 4: 195-208, 1985.
71. Xing RH and Rabbani SA: Overexpression of urokinase receptor in breast cancer results in increased tumor invasion, growth and metastasis. Int J Cancer 67: 423-429, 1996.
72. Fazioli F and Blasi F: Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 15: 25-29, 1994.
73. Ossowski L and Reich E: Experimental model of quantitative study of metastasis. Cancer Res 40: 2300-2309, 1983.
74. Ossowski L and Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-619, 1983.
75. Ossowski L, Russo-Payne H and Wilson EL: Inhibition of urokinase type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 54: 4671-4675, 1994.
76. Wilhelm O, Schmitt M, Höhl S, Senekowitsch R and Graeff H: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 13: 296-302, 1995.
77. Vassalli JD and Belin D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 214: 187-191, 1987.
78. Towle MJ, Lee A, Maduakor EC, Schwartz CE, Bridges AJ and Littlefield BA: Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 53: 2553-2559, 1993.
79. Rabbani SA, Harakidas P, Davidson DJ, Henkin J and Mazar AP: Prevention of prostate-cancer metastasis in vitro by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 63: 840-845, 1995.
80. Lippman ME, Bolan G and Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term culture. Cancer Res 36: 4610-4618, 1976.
81. Horwitz KB: The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocrine Rev 13: 146-163, 1992.
82. Jordan VC: Studies on the estrogen receptor in breast cancer - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36: 267-285, 1995.
83. Lippman ME, Bolan G, Monaco ME, Pinkus L and Engel E: Model systems for the study of estrogen action in tissue culture. J Steroid Biochem 7: 1045-1051, 1976.
84. Watts CKW, Brady A, Sarcevic B, De Fazio A, Musgrove EA and Sutherland RL: Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9: 1804-1813, 1995.
85. Xing RH, Mazar A, Henkin J and Rabbani SA: Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 57: 3585-3593, 1997.
86. Alonso DF, Farias EF, Ladeda V, Davel L, Puricelli L and Bal de Kier JE: Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 40: 209-223, 1996.